Science Group PLC Transaction in Own Shares

RNS Number : 6863K

Science Group PLC

16 April 2024

 

 

 

16 April 2024

 

Science Group plc

(the "Company" or "Science Group")

 

Transaction in own shares

 

 

Science Group plc (AIM:SAG) announces that, on 15 April 2024, it purchased 4,000 of its 1 pence ordinary shares at an average price of 411.0 pence per share. The highest price paid per share was 411.0 pence and the lowest price paid per share was 411.0 pence. The Company purchased these shares through Liberum Capital Limited.

 

The number of shares purchased represented 0.01% of the voting rights attributable to the total ordinary shares in issue prior to the purchase. The purchased shares will be held in treasury.

 

The total number of ordinary shares in issue (excluding treasury shares) following this announcement is 45,736,283.  Science Group holds 449,591 shares in treasury.

 

The figure of 45,736,283 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

 

 

Schedule of Purchases - Individual Transactions

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), the schedule below contains detailed information about the purchases made by Liberum Capital Limited on behalf of the Company as part of the buyback programme.

 

Number of shares purchased	Transaction price (per share)	Time of transaction	Execution venue
1000	411.0	10:09:09	AIMX
3000	411.0	15:19:00	AIMX

 

- Ends -   For further information: Science Group plc Sarah Cole, Company Secretary Tel: [phone]   www.sciencegroup.com   Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) Nick Adams, Fred Walsh, Richard Short Tel: [phone] Liberum Capital Limited (Joint Broker) Max Jones, John More Tel: [phone]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

POSQKPBPPBKDBQD